Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nadunolimab + FOLFIRINOX
- Development stage
- Unknown
- Lead developer
- Cantargia
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
nadunolimab + FOLFIRINOX is an investigational combination therapy for advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). Nadunolimab is a monoclonal antibody targeting the interleukin-1 receptor accessory protein (IL1RAP), designed to block IL1α/IL1β signaling and enhance antibody-dependent cellular cytotoxicity, thereby modulating tumor inflammation and immune evasion. FOLFIRINOX is a multi-agent chemotherapy regimen consisting of folinic acid (leucovorin), fluorouracil (5-FU), irinotecan, and oxaliplatin, each contributing distinct mechanisms targeting DNA synthesis and repair, and cell replication. Preliminary clinical and preclinical studies suggest the combination may provide additive antitumor activity, improved survival, and a reduction in chemotherapy-induced peripheral neuropathy (CIPN), compared to standard regimens. The combination is currently being evaluated in clinical trials, such as CAPAFOUR, for safety, biomarkers, and efficacy in first-line treatment of metastatic PDAC[1][7].
- Other names
- nadunolimab + FOLFIRINOX
02
Targets
TOP1 (DNA Topoisomerase I)IL1RAP (Interleukin 1 receptor accessory protein)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on nadunolimab + FOLFIRINOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nadunolimab + FOLFIRINOX.